The disclosure relates to compositions comprising isolated mitochondria or combined mitochondrial agents, and methods of treating disorders using such compositions.

Among the various aspects of the present disclosure is the provision of compositions of imaging agents and methods for use in detecting, monitoring, and evaluating CCR2 associated diseases, disorders, and conditions.

A visualizable radioactive carbon microsphere (CMS) suspension, a preparation method, and a use thereof are provided. Every 1 mL of the visualizable radioactive CMS suspension includes: CMS: 10 mg to 500 mg; a therapeutic radionuclide with an activity of 5 mCi to 500 mCi; an imaging radionuclide with an activity of 0.1 mCi to 100 mCi; a small organic molecule: 0 mg to 100 mg; and a first solution: 0.1 mL to 1.0 mL. The preparation method mainly includes a process of allowing the CMS to adsorb the small organic molecule, the therapeutic radionuclide, and the imaging zirconium [.sup.89Zr]. The visualizable radioactive CMS suspension can realize both local radiotherapy and real-time imaging of a solid tumor lesion, and thus achieves the visualized treatment of a tumor, which provides a new radioactive CMS product that integrates diagnosis and treatment.

Methods of performing targeted alpha therapy of a cancer patient utilizing actinium-225, methods of preparing a targeted alpha therapy drug that includes actinium-225, methods of preparing actinium-225 from radium-226, and methods of recovering radium-226 from an aqueous produced material stream generated from a natural resource extraction process. The methods of recovering radium-226 include separating the radium-226 from the produced material stream to generate recovered radium-226. The methods of preparing actinium-225 include converting the recovered radium-226 into actinium-225. The methods of preparing the targeted alpha therapy drug include incorporating the actinium-225 into the targeted alpha therapy drug. The methods of performing targeted alpha therapy include treating the cancer patient with the targeted alpha therapy drug.

This disclosure provides design, material, preparation methods, and use alternatives for medical devices. An example method of preparing a stent comprises applying a coating to a portion of the stent at a medical treatment facility, the coating including a plurality of radioactive elements and a substrate. The plurality of radioactive elements are mixed with the substrate to form a mixture such that the plurality of radioactive elements are dispersed within the substrate prior to the coating being applied on the stent.

An ophthalmic radiation device using a polymeric radiation-source implemented as either a polymer molecularly bonded with a radioisotope or a polymeric encasement of a radioisotope.

A method of producing radiobacteria is provided, especially radiolisteria-.sup.32P. Compositions and methods of use thereof are also provided.

The present invention relates to methods for labeling a PSMA binding ligand with a radioactive isotope, preferably .sup.68Ga, .sup.67Ga or .sup.64Cu, said method comprising the steps of: i. providing a single vial comprising, in dried form, said PSMA binding ligand f the following formula (I): (I) at least one buffering agent, sodium chloride and a stabilizer against radiolytic degradation, ii. adding a solution of said radioactive isotope into said single vial, thereby obtaining a solution of said PSMA binding ligand of formula (I) with said radioactive isotope, iii. mixing the solution obtained in ii., and incubating it for a sufficient period of time for obtaining said PSMA binding ligand labelled with said radioactive isotope, and, iv. optionally, adjusting the pH of the solution.

##STR00001##

A radiopeptide is provided which comprises (a) a radionuclide, wherein the radionuclide is terbium-161, (b) a chelator coordinating terbium-161, and (c) a peptide or peptide analogue, which is a somatostatin receptor (SSTR) antagonist. The radiopeptide is suitable for use in the treatment of tumor diseases.

The invention described herein pertains to folate-receptor targeted agents comprising therapeutic agents useful for the treatment of inflammatory disease, including folate-receptor targeted liposomes (folate-targeted liposomes) containing entrapped therapeutic agents and folate-receptor targeted dendrimers conjugated to therapeutic agents (folate-targeted dendrimer conjugates), useful for the treatment of inflammatory disease, including auto-immune disease, as well as to folate-targeted liposomes containing entrapped imaging agents and dendrimer conjugates conjugated to imaging agents, for use in the diagnosis and monitoring of treatment in such disease.